Nomura Asset Management Co. Ltd. Sells 16,576 Shares of DaVita Inc. $DVA

Nomura Asset Management Co. Ltd. cut its holdings in DaVita Inc. (NYSE:DVA) by 91.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,635 shares of the company’s stock after selling 16,576 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in DaVita were worth $186,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of DVA. Norges Bank purchased a new position in shares of DaVita in the fourth quarter valued at about $49,164,000. Arrowstreet Capital Limited Partnership increased its position in shares of DaVita by 109.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after acquiring an additional 289,725 shares during the period. Man Group plc increased its position in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares during the period. Neuberger Berman Group LLC increased its position in shares of DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after acquiring an additional 269,015 shares during the period. Finally, Voloridge Investment Management LLC increased its position in shares of DaVita by 2,905.7% in the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock valued at $30,324,000 after acquiring an additional 220,628 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. TD Cowen lifted their target price on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. UBS Group lifted their target price on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Barclays lifted their target price on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and lifted their target price for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $199.17.

DaVita Price Performance

Shares of NYSE DVA opened at $192.28 on Friday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $202.69. The stock has a market cap of $12.34 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91. The firm has a 50-day moving average of $171.47 and a 200 day moving average of $143.18.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the company posted $2.00 EPS. DaVita’s revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts expect that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.